Compare Ascendis Pharma A/S (ASND) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lululemon Athletica Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Lululemon Athletica Inc trades at $119.11 (market cap $13.54B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LULU | |
|---|---|---|
Market Cap | $17.74B | $13.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $236.51 |
52-Week Low | $163.32 | $105.43 |
Enterprise Value | $18.11B | $14.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lululemon (LULU) trades at $119.26, up 2.36% on the day, showing resilience amid a challenging year where the stock has declined significantly from its highs. The technical picture is neutral with mixed signals from moving averages and oscillators, while fundamentals remain strong with consistent earnings beats, a P/E of 9.66, and robust profitability margins. Recent news highlights board stability after a proxy settlement but also ongoing consumer lawsuits and brand controversies.
The outlook is cautiously optimistic; valuation appears attractive relative to historical levels, and international growth provides upside potential. However, risks include North American market weakness, intense competition, and brand reputation concerns. Analyst consensus leans hold with a $130.53 price target, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
